HER2-low Breast Cancer Clinical Trials
4 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 2
Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
HER2-low Breast Cancer
The First Affiliated Hospital with Nanjing Medical University37 enrolled1 locationNCT07446452
Recruiting
Phase 3
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
HER2-low Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.566 enrolled2 locationsNCT06957886
Recruiting
Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
HER2-low Breast CancerHER2-positive Breast CancerTrastuzumab-rezetecan
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University300 enrolled1 locationNCT07358182
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Breast CancerHER2-low Breast CancerHER2-positive Breast Cancer+1 more
Daiichi Sankyo800 enrolled54 locationsNCT06210776
Recruiting
HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC
HER2-low Breast CancerBreast Cancer Stage IVMolecular Imaging
Renske Altena70 enrolled1 locationNCT06830382
Recruiting
Phase 2
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Breast CancerMetastatic Breast CancerHER2-low Breast Cancer+1 more
Ana C Garrido-Castro, MD357 enrolled11 locationsNCT06533826
Recruiting
Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer
Breast CancerHER2-low Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University255 enrolled1 locationNCT05466786
Recruiting
Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer
Breast NeoplasmsHER2-low Breast CancerAntibody-drug Conjugates
Sun Yat-sen University700 enrolled1 locationNCT06877416